AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04771741
Drug: Acetominophen
RxNorm normalized name: acetominophen 500 MG / dextromethorphan HBr 15 MG / doxylamine succinate 6.25 MG / pseudoephedrine HCl 30 MG per 15 ML Oral Solution
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,000 mg every 6 hours
Trial: NCT04771741
Drug: Toradol
RxNorm normalized name: Toradol
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg every 6 hours, days 0-3
Trial: NCT04771741
Drug: Cyclobenzaprine
RxNorm normalized name: Cyclobenzaprine
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg every 8 hours
Trial: NCT04771741
Drug: Lyrica
RxNorm normalized name: Lyrica
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 75 mg every 12 hours
Trial: NCT04318210
Drug: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
RxNorm normalized name: emtricitabine / tenofovir disoproxil fumarate Pill
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03556631
Drug: live combined Bifidobacterium and Lactobacillus Tablets
RxNorm normalized name: Bifidobacterium animalis / Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
Trial: NCT01360034
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
Trial: NCT02573324
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Capsule
Trial: NCT02573324
Drug: Depatuxizumab mafodotin
RxNorm normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT01455883
Drug: glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral glimepiride does-escalated,if tolerated, to 8 mg/day
Trial: NCT02037503
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02037503
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00785226
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
Trial: NCT01697384
Drug: histrelin acetate
RxNorm normalized name: Histrelin Acetate
DrugBank: Histrelin (DB06788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 52 week implant
Trial: NCT03563040
Drug: Methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)
Trial: NCT00600821
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
Trial: NCT00600821
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
Trial: NCT00600821
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
Trial: NCT00600821
Drug: AG-013736 (axitinib)
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
Trial: NCT00129519
Drug: Imiquimod 5% cream
RxNorm normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
Trial: NCT03526224
Drug: Dimethyl Fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals with MS treated with dimethyl fumarate (Tecfidera)
Trial: NCT03526224
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Individuals with MS treated with teriflunomide (Aubagio)
Trial: NCT02564471
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approve dosing schedule
Trial: NCT02564471
Drug: Atovaquone and Proguanil
RxNorm normalized name: Atovaquone and proguanil only product
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approve dosing schedule
Trial: NCT03347994
Drug: Minnelide
RxNorm normalized name: Minnelide
DrugBank: Minnelide (DB17309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
Trial: NCT01516268
Drug: Sufentanyl
RxNorm normalized name: Sufentanyl
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block.
Trial: NCT04132349
Drug: Ulipristal Acetate 5 mg
RxNorm normalized name: ulipristal acetate 5 MG
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
Trial: NCT01595516
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks
Trial: NCT01595516
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks
Trial: NCT02096835
Drug: Tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be given at the start of skin closure
Trial: NCT02096835
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will be given after induction
Trial: NCT01312909
Drug: Varenicline 1mg BID
RxNorm normalized name: varenicline 1 MG
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
Trial: NCT01312909
Drug: Varenicline 0.5mg BID
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
Trial: NCT03540901
Drug: ACETAZOLAMIDE oral capsule
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
Trial: NCT00659646
Drug: Levofloxacin only
RxNorm normalized name: Levofloxacin only product
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
Trial: NCT05517239
Drug: Gemcitabine, Oxaliplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
Trial: NCT00509197
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 250mcg bid for one month
Trial: NCT00244244
Drug: arimoclomol
RxNorm normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01696630
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01696630
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00796029
Drug: 14C-paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01557660
Drug: inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.6mg/mL inhalation solution, up to 12 breaths four times a day
Trial: NCT01260610
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg of Tenofovir daily
Trial: NCT01260610
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg of Telbivudine daily
Trial: NCT01260610
Drug: Tenofovir plus Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
Trial: NCT01513772
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
Trial: NCT01278459
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 week treatment, 20mg/day taken orally in tablet form
Trial: NCT02309385
Drug: 8% Dexamethasone Sodium Phosphate - Visulex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02309385
Drug: 15% Dexamethasone Sodium Phosphate - Visulex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03285646
Drug: Fasinumab
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) every 4 weeks (Q4W)
Trial: NCT03599427
Drug: systemic lidocaine
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
Trial: NCT00961259
Drug: Fenofibric Acid 35 mg Tablet
RxNorm normalized name: fenofibrate
DrugBank: Fenofibric acid (DB13873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 35 mg tablet administered after an overnight fast of at least 10 hours
Trial: NCT00961259
Drug: Fenofibric Acid 35 mg Tablet
RxNorm normalized name: fenofibrate
DrugBank: Fenofibric acid (DB13873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 x 35 mg tablets administered after an overnight fast of at least 10 hours
Trial: NCT00961259
Drug: Fenofibric Acid 105 mg Tablet
RxNorm normalized name: fenofibrate
DrugBank: Fenofibric acid (DB13873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 105 mg tablet administered after an overnight fast of at least 10 hours
Trial: NCT03660046
Drug: Depot medroxyprogesterone acetate (DMPA)
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
Trial: NCT03660046
Drug: Etonogestrel implant (Eng-Implant)
RxNorm normalized name: etonogestrel Drug Implant
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
Trial: NCT03660046
Drug: Levonorgestrel IUD (Lng-IUD)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
Trial: NCT03004534
Drug: darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
Trial: NCT00491244
Drug: Peginterferon alfa-2a and ribavirin
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
Trial: NCT00491244
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
Trial: NCT02984397
Drug: Ketotifen Fumarate
RxNorm normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
Trial: NCT00985348
Drug: Levetiracetam (Keppra)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose
Trial: NCT01788540
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
Trial: NCT03243331
Drug: Gedatolisib
RxNorm normalized name: Gedatolisib
DrugBank: Gedatolisib (DB11896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
Trial: NCT03243331
Drug: PTK7-ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
Trial: NCT01785524
Drug: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training
RxNorm normalized name: tamarind juice
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
Trial: NCT02870218
Drug: Nicotine discrimination thresholds
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
Trial: NCT01163734
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous treatment followed oral treatment for 13 days.
Trial: NCT01421810
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg PO
Trial: NCT00812812
Drug: paroxetine 10mg tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 tablet(s) once a day
Trial: NCT00812812
Drug: paroxetine 20mg tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet once a day
Trial: NCT00812812
Drug: matched placebo to paroxetine 10mg
RxNorm normalized name: paroxetine mesylate 10 MG
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets once a day
Trial: NCT00812812
Drug: matched placebo to paroxetine 20mg
RxNorm normalized name: paroxetine hydrochloride 20 MG
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet once a day
Trial: NCT00778830
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
Trial: NCT00772174
Drug: Pioglitazone and Metformin
RxNorm normalized name: Pioglitazone and Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
Trial: NCT00772174
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
Trial: NCT02960880
Drug: Rivaroxaban (Xarelto, BAY597939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg, 20mg
Trial: NCT02960880
Drug: Phenprocoumon (branded and generics)
RxNorm normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually adjusted dose
Trial: NCT00801684
Drug: TrIP-2SS + Foradil
RxNorm normalized name: formoterol fumarate Inhalation Powder [Foradil]
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Trial: NCT02691858
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
Trial: NCT01281488
Drug: indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00375193
Drug: Amrubicin
RxNorm normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
Trial: NCT01377974
Drug: Miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Capsule of 50mg, taken orally 2 times a day for 28 days
Trial: NCT01377974
Drug: Standard Treatment Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
Trial: NCT00485875
Drug: Atomoxetine Hydrochloride
RxNorm normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00343187
Drug: Vehicle Control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01698697
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
Trial: NCT02714049
Drug: flibanserin
RxNorm normalized name: Flibanserin
DrugBank: Flibanserin (DB04908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women